| P/E (FY) | — | Sales (TTM) | $69.2M |
| Earnings (TTM) | -$62.0M | ROE | −84.63% |
| Net Margin | −125.36% | ROIC | −108.75% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −8.82% |
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for virology and immunology. Its pipeline includes EDP-514 for chronic hepatitis B, zelicapavir and EDP-323 for respiratory syncytial virus, EDP-235 for human coronaviruses, EDP-978 for chronic spontaneous urticaria, the protease inhibitor Glecaprevir for hepatitis C, and EPS-3903 for atopic dermatitis. The company has a collaborative development and license agreement with Abbott Laboratories.
| Market Cap | $366.7M | Trading Days | 3356 |
| 52W High | 17.15 |
| 52W Low | 6.45 |
| % Off High | −26.47% |
| YTD | −20.04% | 1Y | 57.04% |
| 3Y | −31.62% | 5Y | −70.32% |
| 10Y | −39.95% | Since incept. (ann.) | −2.29% |
Royalty 100%
| Ann. Volatility (1Y) | 109.48% | Ann. Volatility (3Y) | 83.40% |
| Sharpe (1Y) | 0.82 | Sharpe (3Y) | 0.21 |
| Max Drawdown (1Y) | −34.30% | Max Drawdown (3Y) | −78.51% |
| Beta (3Y, vs SPY) | 1.53 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NATR | NATURES SUNSHINE PRODUCTS INC | $364.7M | 19.6 |
| PRLD | Prelude Therapeutics Inc | $369.6M | — |
| AVIR | Atea Pharmaceuticals, Inc. | $360.9M | — |
| DMAC | DiaMedica Therapeutics Inc. | $357.8M | — |
| EBS | Emergent BioSolutions Inc. | $377.2M | 7.9 |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $380.5M | — |
| KROS | Keros Therapeutics, Inc. | $381.2M | 4.4 |
| UPB | Upstream Bio, Inc. | $348.3M | — |
| ABEO | ABEONA THERAPEUTICS INC. | $343.1M | 6.0 |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $342.9M | — |
| AKBA | Akebia Therapeutics, Inc. | $340.7M |
| LRMR | Larimar Therapeutics, Inc. | $397.9M | — |
